- Financial Times•yesterday
Takeda, Japan's largest drugmaker, has outsourced the development of a drug for rare forms of childhood epilepsy to a US biotech company in an unusual deal that underscores the growing importance of smaller ...
- Zacks•8 days ago
Several licensing deals and agreements were announced this week including the $5.2 billion ARIAD (ARIA) acquisition.
- American City Business Journals•8 days ago
Harvey Berger, the co-founder and longtime former CEO of Ariad Pharmaceuticals, is taking something of a victory lap after the Cambridge biotech was acquired by Japanese drug giant Takeda for $5.2 billion on Monday. Berger retired at the end of 2015 following an intense proxy battle waged by Alex Denner, the head of hedge fund Sarissa Capital. In fact, he said there were "active discussions" with multiple suitors during his final year at the company, including with Takeda.
TKPYY : Summary for TAKEDA PHARMACEUTI SPON ADR EA - Yahoo Finance
Takeda Pharmaceutical Company Limited (TKPYY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||20.20 - 20.70|
|52 Week Range||19.96 - 25.40|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||24.29|
|Dividend & Yield||0.78 (3.69%)|
|1y Target Est||N/A|